Cargando…

Escherichia coli adhesin protein-conjugated thermal responsive hybrid nanoparticles for photothermal and immunotherapy against cancer and its metastasis

BACKGROUND: Advanced cancer therapy is targeted at primary tumors and also recurrent or metastatic cancers. Combinational cancer treatment has recently shown high efficiency against recurrent and metastatic cancers. In this study, we synthesized a thermal responsive hybrid nanoparticle (TRH) contain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Juyoung, Zhang, Wei, Park, Hae-Bin, Yadav, Dhananjay, Jeon, Yong Hyun, Jin, Jun-O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261870/ https://www.ncbi.nlm.nih.gov/pubmed/34230112 http://dx.doi.org/10.1136/jitc-2021-002666

Ejemplares similares

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

Quantifying the impact of immunotherapy on RNA dynamics in cancer
por: Usaite, Ieva, et al.
Publicado: (2023)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022)

Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy
por: Beyranvand Nejad, Elham, et al.
Publicado: (2020)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
por: Beyranvand Nejad, Elham, et al.
Publicado: (2021)

Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
por: Cubas, Rafael, et al.
Publicado: (2020)

Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4
por: Marshall, Lisa A, et al.
Publicado: (2020)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy
por: Choudhury, Ruhul H, et al.
Publicado: (2022)

Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
por: Krieg, Carsten, et al.
Publicado: (2022)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
por: Boelaars, Kelly, et al.
Publicado: (2023)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Lejeune, Pascale, et al.
Publicado: (2021)

An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
por: Wittwer, Nicole L, et al.
Publicado: (2023)

Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
por: Liu, Hsin-Yu, et al.
Publicado: (2021)

Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
por: Zhu, Lin, et al.
Publicado: (2022)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
por: Bao, Xuanwen, et al.
Publicado: (2020)

An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy
por: Wang, Hui, et al.
Publicado: (2020)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
por: Lo, Amy A, et al.
Publicado: (2021)

Curli fimbria: an Escherichia coli adhesin associated with human cystitis
por: Cordeiro, Melina Aparecida, et al.
Publicado: (2016)

CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
por: Zammarchi, Francesca, et al.
Publicado: (2020)

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
por: Marcu, Ana, et al.
Publicado: (2021)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

Combinatorial immunotherapy induces tumor-infiltrating CD8(+) T cells with distinct functional, migratory, and stem-like properties
por: Van Braeckel-Budimir, Natalija, et al.
Publicado: (2021)

Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy
por: van Elsas, Marit J, et al.
Publicado: (2023)

Implication of (99m)Tc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells
por: Gao, Yu, et al.
Publicado: (2023)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

Escherichia coli Aggregates Mediated by Native or Synthetic Adhesins Exhibit Both Core and Adhesin-Specific Transcriptional Responses
por: Chekli, Yankel, et al.
Publicado: (2023)

Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies
por: Odunsi, Adekunle, et al.
Publicado: (2020)

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
por: Lopes, Jared E, et al.
Publicado: (2020)

System analysis based on the cancer–immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma
por: Wang, Xu, et al.
Publicado: (2022)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023)

Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
por: Finisguerra, Veronica, et al.
Publicado: (2023)

Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
por: Zhang, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_57355ljoqjiq2cbgvm9mh62h71